On the Centennial of Vitamin D-Vitamin D, Inflammation, and Autoimmune Thyroiditis: A Web of Links and Implications

Nutrients. 2022 Nov 26;14(23):5032. doi: 10.3390/nu14235032.

Abstract

The 100th anniversary of the discovery of vitamin D3 (VitD3) coincides with significant recent advances in understanding its mechanism of action along with accumulating knowledge concerning its genomic and nongenomic activities. A close relationship between VitD3 and the immune system, including both types of immunity, innate and adaptive, has been newly identified, while low levels of VitD3 have been implicated in the development of autoimmune thyroiditis (AIT). Active 1,25(OH)2 D3 is generated in immune cells via 1-α-hydroxylase, subsequently interacting with the VitD3 receptor to promote transcriptional and epigenomic responses in the same or adjacent cells. Despite considerable progress in deciphering the role of VitD3 in autoimmunity, its exact pathogenetic involvement remains to be elucidated. Finally, in the era of coronavirus disease 2019 (COVID-19), brief mention is made of the possible links between VitD3 deficiency and risks for severe COVID-19 disease. This review aims to commemorate the centennial of the discovery of VitD3 by updating our understanding of this important nutrient and by drawing up a framework of guidance for VitD3 supplementation, while emphasizing the necessity for personalized treatment in patients with autoimmune thyroid disease. A tailored approach based on the specific mechanisms underlying VitD3 deficiency in different diseases is recommended.

Keywords: 1-α-hydroxylase; TSH; antithyroglobulin antibodies; antithyroid peroxidase antibodies; autoimmune thyroiditis; vitamin D.

Publication types

  • Review

MeSH terms

  • COVID-19*
  • Cholecalciferol
  • Hashimoto Disease*
  • Humans
  • Inflammation
  • Thyroiditis, Autoimmune*
  • Vitamin D
  • Vitamin D Deficiency*
  • Vitamins

Substances

  • Vitamin D
  • Vitamins
  • Cholecalciferol

Grants and funding

This research received no external funding.